首页> 外文期刊>Bone marrow transplantation >Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia
【24h】

Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia

机译:移植物与宿主疾病对小儿白血病同种异体干细胞移植后复发和存活的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Graft-versus-host disease (GVHD) occasionally leads to morbidity and mortality but is thought to reduce the risk of relapses in patients with a hematological malignancy. However, information on the effect of GVHD in pediatric leukemia is limited. Using a nationwide registry, we retrospectively analyzed 1526 children who underwent allogeneic stem cell transplantation for leukemia. Grades 0-I acute GVHD were associated with a higher relapse rate at three years after transplantation, at 25.4 and 24.3%, respectively, than grades II, III, or IV acute GVHD at 18.9%, 21.2%, and 2.6%, respectively. In contrast, the overall survival curve of the grades 0 and I GVHD groups (79.0% and 79.5%, respectively) approximated that of the grade II GVHD group (76.3%), and the probability of survival was worst in the severe GVHD groups (66.9% for grade III and 42.5% for grade IV). Chronic GVHD also reduced the relapse risk but conferred no survival advantage. Acute lymphoblastic leukemia was more sensitive to acute GVHD than acute myeloid leukemia (AML) while AML was more sensitive to chronic GVHD. Our study reproduced the preventive effects of GVHD against pediatric leukemia relapses but failed to demonstrate a significant survival advantage.
机译:移植物与宿主疾病(GVHD)偶尔会导致发病率和死亡率,但被认为降低血液恶性肿瘤患者复发的风险。然而,有关GVHD在儿科白血病的影响的信息是有限的。使用全国注册处,我们回顾性地分析了1526名接受白血病的同种异体干细胞移植的儿童。级别0-I急性GVHD在移植后三年,分别在25.4和24.3%以上,分别为18.9%,III级,21.2%和2.6%。相比之下,等级0和I GVHD组的总存活曲线(分别为79.0%和79.5%)近似于II级GVHD组(76.3%),并且在严重的GVHD组中存活的概率最差( III级的66.9%和第四级的42.5%)。慢性GVHD还减少了复发风险,但没有赋予生存优势。急性淋巴细胞白血病对急性GVHD比急性髓性白血病(AML)更敏感,而AML对慢性GVHD更敏感。我们的研究再现GVHD对儿科白血病复发但未表现出显着的生存优势的预防效果。

著录项

  • 来源
    《Bone marrow transplantation》 |2019年第1期|共8页
  • 作者单位

    Natl Ctr Child Hlth &

    Dev Childrens Canc Ctr Tokyo Japan;

    Japanese Data Ctr Hematopoiet Cell Transplantat Nagoya Aichi Japan;

    Kyoto Univ Grad Sch Med Dept Hematol &

    Oncol Kyoto Japan;

    Japanese Red Cross Nagoya First Hosp Dept Hematol &

    Oncol Childrens Med Ctr Nagoya Aichi Japan;

    Natl Ctr Child Hlth &

    Dev Childrens Canc Ctr Tokyo Japan;

    Fujita Hlth Univ Dept Pediat Toyoake Aichi Japan;

    Japanese Red Cross Nagoya First Hosp Dept Hematol &

    Oncol Childrens Med Ctr Nagoya Aichi Japan;

    Shizuoka Childrens Hosp Dept Hematol &

    Oncol Shizuoka Japan;

    Keio Univ Dept Pediat Sch Med Tokyo Japan;

    Natl Kyushu Canc Ctr Dept Pediat Fukuoka Fukuoka Japan;

    Saitama Childrens Med Ctr Dept Hematol Oncol Saitama Japan;

    Kanagawa Childrens Med Ctr Div Hematooncol Regenerat Med Yokohama Kanagawa Japan;

    Ibaraki Childrens Hosp Dept Hematol Oncol Mito Ibaraki Japan;

    Hokkaido Univ Hosp Dept Pediat Sapporo Hokkaido Japan;

    Tokyo Metropolitan Childrens Med Ctr Dept Hematol Oncol Tokyo Japan;

    Niigata Canc Ctr Hosp Dept Pediat Niigata Japan;

    Osaka City Gen Hosp Dept Pediat Hematol &

    Oncol Osaka Japan;

    Osaka Womens &

    Childrens Hosp Dept Hematol Oncol Izumi Japan;

    Osaka Univ Dept Pediat Grad Sch Med Suita Osaka Japan;

    Hokkaido Univ Dept Hematol Fac Med Sapporo Hokkaido Japan;

    Nagoya Univ Dept Hematol &

    Oncol Grad Sch Med Nagoya Aichi Japan;

    Japanese Data Ctr Hematopoiet Cell Transplantat Nagoya Aichi Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号